Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Its biggest would-be competitor is ivonescimab, a medicine being developed in the U.S. by Summit Therapeutics. It delivered positive clinical trial results in China in a phase 3 study in which it went ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.